Innovative Drug
Developing next-generation antibody therapeutics to address
unmet medical needs
Prestige Biopharma is developing differentiated antibody therapeutics to address life-threatening diseases and unmet medical needs.
18
Innovative Drug Pipelines
Pipeline
Modality
Indiaction
Development Stage
PBP1510
First-in-Class
PDAC
Phase 1/2a
PBP1710
First-in-Class
Solid Tumor, Fibrosis
Preclinical
IDC007
Bispecific Antibody
CRS
CLD
IDC331
Novel Concept Antibody
Solid Tumor
PoC
IDC332
Novel Concept Antibody
Solid Tumor
PoC
IDC333
Novel Concept Antibody
Solid Tumor
PoC
IDC111
First-in-Class
Solid Tumor
Discovery
IDC112
First-in-Class
Solid Tumor
Discovery
IDC113
First-in-Class
Solid Tumor
Discovery
IDC114
First-in-Class
Infectious diseases
Discovery
IDC115
First-in-Class
Infectious diseases
Discovery
IDC334
Novel Concept Antibody
Solid Tumor
Discovery
IDC441
ADC
Solid Tumor
Discovery
IDC001
Bispecific Antibody
Solid Tumor
Discovery
IDC002
Bispecific Antibody
Solid Tumor
Discovery
IDC003
Bispecific Antibody
Solid Tumor
Discovery
IDC008
Bispecific Antibody
Solid Tumor
Discovery
IDC009
Bispecific Antibody
Solid Tumor
Discovery
Pipeline
| Modality | Indication |
|---|---|
| First-in-Class | PDAC |
| Development Phase |
|---|
| Phase 1/2a |
Pipeline
| Modality | Indication |
|---|---|
| First-in-Class | Solid Tumor |
| Fibrosis |
| Development Stage |
|---|
| Preclinical |
Pipeline
| Modality | Indication |
|---|---|
| Bispecific antibody | CRS |
| Development Stage |
|---|
| CLD |
Pipeline
| Modality | Indication |
|---|---|
| Novel Concept Antibody | Solid Cancer |
| Development Stages |
|---|
|
PoC |
Pipeline
| Modality | Indication |
|---|---|
| First-in-class | Solid cancer |
| Development Stage |
|---|
| PoC |
Pipeline
| Modality | Indication |
|---|---|
| Novel Concept Antibody |
Solid Cancer |
| Development Stage |
|---|
| PoC |
Pipeline
| Modality | Indication |
|---|---|
| First-in-class | Solid cancer |
| Development Stage |
|---|
| Discovery |
Pipeline
| Modality | Indication |
|---|---|
| First-in-class | Solid cancer |
| Development Stage |
|---|
| Discovery |
Pipeline
| Modality | Indication |
|---|---|
| First-in-class | Solid cancer |
| Development Stage |
|---|
| Discovery |
Pipeline
| Modality | Indication |
|---|---|
| First-in-class | Immunology, Cardiovascular, Solid Tumor |
| Development Stage |
|---|
| Discovery |
Pipeline
| Modality | Indication |
|---|---|
| First-in-class | Immunology, Solid Tumor |
| Development Stage |
|---|
| Discovery |
Pipeline
| Modality | Indication |
|---|---|
| Novel Concept Antibody |
Solid Cancer |
| Development Stage |
|---|
| Discovery |
Pipeline
| Modality | Indication |
|---|---|
| Novel Concept Antibody |
Solid Cancer |
| Development Stage |
|---|
| Discovery |
Pipeline
| Modality | Indication |
|---|---|
| Bispecific antibody | Solid Cancer |
| Development Stage |
|---|
|
Discovery |
Pipeline
| Modality | Indication |
|---|---|
| Bispecific antibody | Solid Cancer |
| Development Stage |
|---|
|
Discovery |
Pipeline
| Modality | Indication |
|---|---|
| Bispecific antibody | Solid Cancer |
| Development Stage |
|---|
|
Discovery |
Pipeline
| Modality | Indication |
|---|---|
| Bispecific antibody | Solid Cancer |
| Development Stage |
|---|
|
Target VD |
Pipeline
| Modality | Indication |
|---|---|
| Bispecific antibody | Solid Cancer |
| Development Stage |
|---|
|
Target VD |